Kyung Nam PharmLtd Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Oh Hwan

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Revenues Not Telling The Story For Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) After Shares Rise 29%

Nov 11

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected

Aug 19

Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price

May 21

Does Kyung Nam PharmLtd (KOSDAQ:053950) Have A Healthy Balance Sheet?

Mar 21

CEO

Oh Hwan

no data

Permanencia

Mr. Oh Chang Hwan has been the Chief Executive Officer of Kyung Nam Pharm Co.,Ltd. since January 22, 2013.

Kyung Nam PharmLtd Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Revenues Not Telling The Story For Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) After Shares Rise 29%

New major risk - Shareholder dilution

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected

Less than half of directors are independent

Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price

RFTech Co., Ltd. Bionanotechnology Co., Ltd. and Lee Gyeong Sook agreed to acquire a 32.69% stake in Enterpartners Co., LTD (KOSDAQ:A058450) from Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) for KRW 23 billion.

RFTech Co., Ltd. Bionanotechnology Co., Ltd. and Lee Gyeong Sook agreed to acquire a 32.69% stake in Enterpartners Co., LTD (KOSDAQ:A058450) from Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) for KRW 23 billion

Does Kyung Nam PharmLtd (KOSDAQ:053950) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Less than half of directors are independent

Less than half of directors are independent

Full year 2020 earnings released: ₩318 loss per share (vs ₩293 loss in FY 2019)

New 90-day low: ₩7,730

New 90-day high - ₩11,350

New 90-day low - ₩7,150

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950), Virtualtek Corp (KOSDAQ:A036620) and Ventage Partners Co., Ltd. agreed to acquire 9.32% stake in Livefinancial Co.,Ltd. (KOSDAQ:A036170) for KRW 5.8 billion.

CEO

Permanencia